Several major U.S.-based companies are urgently seeking alternative sources for compendial plant-based ingredients-especially low-concentrate powders-to mitigate the risk of stockouts and margin pressure caused by steep import tariffs on Chinese-origin products.

Last week, Eevia received multiple large-scale requests for quotation (RFQs) from leading U.S. buyers scrambling to secure European-origin supply. While the current U.S. tariff measures are widely viewed as temporary, uncertainty around their duration and scope has triggered a surge in near-term purchasing activity and forward-looking procurement strategies from nervous procurement managers.

"The market has suddenly shifted," said Stein Ulve, CEO of Eevia Health. "U.S. buyers who previously relied on Chinese suppliers are now urgently looking to Europe for which tariffs are significantly lower."

Eevia expects the situation to generate possible short-term sales opportunities, especially for low-concentrate extracts and powders, where Chinese suppliers have traditionally dominated the volume segment. The Company is currently evaluating logistics capacity and raw material availability to accommodate potential contract volumes significantly larger than normal order sizes. This unexpected development may help elevate Eevia's strategic position as a trusted European source of sustainable nutraceutical ingredients and highlights the importance of regional supply chain resilience in the global health ingredients sector.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com                      

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.